These results demonstrated that coprescription of CYP3A4-metabolized statin and CCBs that inhibit CYP3A4 independently contributed to acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke. The gene discussed is CYP3A4; the disease is Hyperkalemia.